All In Biotech

BLA 761115 · Immunomedics INC

Trodelvy

Sacituzumab Govitecan-Hziy · Injection

NovelBreakthrough therapyAccelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Apr 22, 2020

Approved uses

8

Original approval plus efficacy supplements

Registered trials

151

23 Phase 3, 71 recruiting

FAERS reports

4,834

4,329 serious, 1,014 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NEUTROPENIA AND DIARRHEA TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia [see Dosage and Administration (2.4) ] . Initiate anti-infective treatment in patients with febrile neutropenia without delay [see Warnings and Precautions (5.1) ]. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide [see Warnings and Precautions (5.2) ]. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses [see Dosage and Administration...

What it is approved for

From the label in effect Jun 24, 2026.

TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. ( 1.1 , 14.1 ) In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test. ( 1.1 , 14.1 ) Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) 1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy. TRODELVY, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable...

Mechanism: Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanized antibody that recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker. Pharmacology data suggest that sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 24, 2026 Supplement 64 · Efficacy LetterLabel
  • Jun 24, 2026 Supplement 63 · Efficacy LetterLabel
  • Nov 22, 2024 Supplement 58 · Efficacy · priority review LabelLetter
  • Feb 3, 2023 Supplement 35 · Efficacy · priority review LabelLetter
  • Apr 13, 2021 Supplement 9 · Efficacy · priority review LabelLetter
  • Apr 7, 2021 Supplement 13 · Efficacy · priority review LetterLabel
  • Apr 7, 2021 Supplement 5 · Efficacy · priority review LetterLabel
  • Apr 22, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
1 products under this application
  • TRODELVY · SACITUZUMAB GOVITECAN-HZIY 180MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sacituzumab Govitecan" as an intervention, any sponsor and status, largest first.

All 151 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • disease progression1,368
  • diarrhoea615
  • neutropenia549
  • death491
  • nausea281
  • fatigue273
  • triple negative breast cancer229
  • febrile neutropenia219
  • asthenia217
  • off label use207
  • alopecia176
  • inappropriate schedule of product administration170

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20192
2020112
2021397
20221,248
2023579
2024714
2025967
2026815

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trodelvy (Sacituzumab Govitecan-Hziy)

2024 spending

$6.2M

Beneficiaries

67

319 claims

Per beneficiary

$92,888

$2,399.18 per unit

View as table
YearSpending
2020$852,092
2021$1,908,219
2022$3,041,189
2023$4,567,680
2024$6,223,470

Part B: Trodelvy (Sacituzumab Govitecan-Hziy) · HCPCS J9317

2024 spending

$272M

Beneficiaries

3,300

28,257 claims

Per beneficiary

$82,521

2024 ASP limit $34.29 per unit

View as table
YearSpending
2020$0
2021$96,029,681
2022$156,284,895
2023$230,777,754
2024$272,318,588

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 100 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.